RT Journal Article
SR Electronic
T1 Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.23.20160762
DO 10.1101/2020.07.23.20160762
A1 Aguas, Ricardo
A1 Corder, Rodrigo M.
A1 King, Jessica G.
A1 Gonçalves, Guilherme
A1 Ferreira, Marcelo U.
A1 Gomes, M. Gabriela M.
YR 2020
UL http://medrxiv.org/content/early/2020/11/16/2020.07.23.20160762.abstract
AB As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads, the susceptible subpopulation declines causing the rate at which new infections occur to slow down. Variation in individual susceptibility or exposure to infection exacerbates this effect. Individuals that are more susceptible or more exposed tend to be infected and removed from the susceptible subpopulation earlier. This selective depletion of susceptibles intensifies the deceleration in incidence. Eventually, susceptible numbers become low enough to prevent epidemic growth or, in other words, the herd immunity threshold is reached. Here we fit epidemiological models with inbuilt distributions of susceptibility or exposure to SARS-CoV-2 outbreaks to estimate basic reproduction numbers (R0) alongside coefficients of individual variation (CV) and the effects of containment strategies. Herd immunity thresholds are then calculated as 1 − (1/R0)1/(1+CV2) or 1 − (1/R0)1/(1+2CV2), depending on whether variation is on susceptibility or exposure. Our inferences result in herd immunity thresholds around 10-20%, considerably lower than the minimum coverage needed to interrupt transmission by random vaccination, which for R0 higher than 2.5 is estimated above 60%. We emphasize that the classical formula, 1 − 1/R0, remains applicable to describe herd immunity thresholds for random vaccination, but not for immunity induced by infection which is naturally selective. These findings have profound consequences for the governance of the current pandemic given that some populations may be close to achieving herd immunity despite being under more or less strict social distancing measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR.M.C. and M.U.F. receive scholarships from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologio (CNPq), Brazil.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets are publicly available at the respective national ministry of health websites. https://github.com/mgmgomes1/covid